Medical giant Johnson & Johnson (JNJ) said Tuesday that it’s restructuring its device division in a bid to save up to $1 billion annually by the end of 2018. J&J didn’t provide many details in its press release, saying that it will discuss the project further when it reports its Q4 earnings on Jan. 26. However, it did specify that the move will involve trimming 4% to 6% of the unit’s global workforce over the next two years, amounting to about
Trekkies beware: 2016 might be the year of the Borg, and fittingly so, because in the shifting chip landscape, “resistance is futile.” Harvard University’s Wyss Institute developed organs-on-chips in 2010. Today, the program is more tangible. In 2015, the institute picked up a partnership with Johnson & Johnson (JNJ) for pre-clinical trial testing. And drug companies are taking notice. The chips, lined with human cells, can test human responses to
Look for Alphabet’s (GOOGL) Google to soon disclose more plans in its medical robotics partnership with Johnson & Johnson (JNJ), which eventually could pressure Intuitive Surgical’s (ISRG) stock. Shares of Sunnyvale, Calif.-based Intuitive Surgical, the leading maker of medical robotics systems, are down nearly 4% in 2015.